NYSE: JNJJohnson & Johnson Stock
$148.53-1.03 (-0.69%)
Updated Apr 24, 2024
JNJ Price
$148.53
Fair Value Price
N/A
Market Cap
$357.77B
52 Week Low
$143.13
52 Week High
$175.97
P/E
10.7x
P/B
5.2x
P/S
4.66x
PEG
N/A
Dividend Yield
3.2%
Revenue
$85.16B
Earnings
$35.15B
Gross Margin
68.8%
Operating Margin
44.22%
Profit Margin
41.3%
Debt to Equity
1.44
Operating Cash Flow
$23B
Beta
0.52
Next Earnings
N/A
Ex-Dividend
May 20, 2024
Next Dividend
Jun 4, 2024
JNJ Overview
Johnson & Johnson manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases. Other offerings include oral care, baby care, beauty, over-the-counter pharmaceutical, women's health, and wound care products, as well as medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. It distributes its products to retailers, wholesalers, health care professionals, and hospitals. J&J was founded in 1886 and is headquartered in New Brunswick, NJ.
Zen Score
–
Industry Average (43)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how JNJ scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JNJ is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
JNJ is good value based on its earnings relative to its share price (10.7x), compared to the US market average (41.27x)
P/E vs Market Valuation
JNJ is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more JNJ due diligence checks available for Premium users.
Be the first to know about important JNJ news, forecast changes, insider trades & much more!
JNJ News
Valuation
JNJ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
10.7x
Industry
153.97x
Market
41.27x
JNJ is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
JNJ is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
JNJ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.2x
Industry
5.95x
JNJ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
JNJ's financial health
Profit margin
Revenue
$13.5B
Net Income
$4.0B
Profit Margin
29.9%
JNJ's Earnings (EBIT) of $37.66B... subscribe to Premium to read more.
Interest Coverage Financials
JNJ's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$167.6B
Liabilities
$98.8B
Debt to equity
1.44
JNJ's short-term assets ($53.50B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JNJ's short-term assets ($53.50B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JNJ's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
JNJ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.9B
Investing
-$1.2B
Financing
-$4.7B
JNJ's operating cash flow ($22.79B)... subscribe to Premium to read more.
Debt Coverage Financials
JNJ vs General Drug Manufacturer Stocks
Johnson & Johnson Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.